ERBB2 and breast carcinoma: Subsequently, these researchers extended their findings that EGCG attenuated EGFR 2 (HER2) or/and EGFR 3 (HER3)-induced FASN overexpression in breast cancer cells through suppressing PI3K/Akt signaling (219).